Skip to main content
A close up image of two people holding hands in support


Cannabinoids and Anxiety
We see great potential for clinical trials of cannabinoids for mental health disorders, thanks to its ability to reduce anxiety and psychosis. The precise mechanism by which the endocannabinoid system modulates anxiety and depression is not fully understood, so further research is already underway.

Our Research

Cannabidiol for adolescent anxiety (CAPS)

This study is a single-centre, 12-week open-label trial of CBD for anxiety disorders. Participants are young people aged 12 – 25 years with a DSM-5 diagnosis of an anxiety disorder who do not respond to evidence-based standard treatment (e.g. CBT or CBT plus SSRIs/SSNRIs). CBD is administered on a fixed–flexible schedule adjusted up to a maximum dose. Each participant will be offered biweekly CBT for 12 weeks (5 sessions). The trial is being conducted at the Headspace Glenroy facility according to Good Clinical Practice guidelines, overseen by the trial sponsor, Orygen – The National Centre of Excellence in Youth Mental Health study service unit.

This is a collaboration between the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney; and Orygen, The National Centre of Excellence in Youth Mental Health.

Chief Investigator: Professor Paul Amminger (Orygen)

Project Coordinators: Dr Maximus Berger (Orygen) & Emily Li (Orygen)

For further information, please contact: